anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 4. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word or face.
Patients receive a single dose of vismodegib PO after eating a low fat meal. Beginning 7 days later, patients receive vismodegib PO after eating a meal daily on days 1-28.
High Protein-enriched Enteral Nutrition: polymeric infant formula (Infatrini; Nutricia, Madrid, Spain) supplemented with 2.6 g of protein/100 mL of formula. The source of the protein supplement would be a nonhydrolyzed protein cow's milk-based formula (Resource Protein Instant; Nestlé, Barcelona, Spain). Final composition 5.1 g/100 mL.
OBJECTIVE: This series of audits aimed to determine current best practice in delirium management in a tertiary teaching hospital and to identify strategies to improve the quality of care in delirium with a focus on prevention.
METHODS: We completed a series of audits following the formation of the Cognitive Impairment Reference Group, a multidisciplinary team that was created to implement delirium management guidelines and monitor compliance. Audit 1 focused on antipsychotic use in patients aged 66 years and older. Audit 2 reviewed delirium care in the Acute Medical Ward. Audit 3 included ethnographic data and investigated the use of non-pharmacological methods to prevent and manage delirium in the Geriatric Ward. Two years on, Audit 4 is a repeat of Audit 1.
RESULTS: There were improved rates of cognitive screening between Audits 2 and 3 from 65% n = 40 to 86% n = 102, respectively. Most patients had one form of non-pharmacological strategy in place to prevent delirium however few had a multicomponent approach. Fewer patients were prescribed benzodiazepines alongside antipsychotics 28.57% n = 35 in Audit 1 compared to Audit 4 12.5% n = 32.
CONCLUSIONS: Improved quality of care in delirium management is achievable via a co-ordinated multidisciplinary approach. These audits demonstrated improvements in both rates of cognitive screening, and use of non-pharmacological strategies prior to antipsychotic medication use and better adherence to guidelines for antipsychotic prescribing. Areas for further development in delirium prevention include the uptake of screening and individualised non-pharmacological strategies.
Will receive LAIV this year. Includes 5-8 year olds and approximately half of the 9-17 year olds. Prior history includes vaccine failures, vaccinated/uninfected and unvaccinated/uninfected last year. PBMC available for those who were infected last year, all ages.
The invention discloses a knowledge-driven drug recycling system based on a comprehensive drug knowledge map. The method designs and develops the medicine knowledge graph by systematically integrating a plurality of medicine knowledge bases, and constructs the artificial intelligent algorithm of the biomedical knowledge graph. The present invention utilizes a method based on path search and embedded data representation to construct drug knowledge maps and mine valuable information therefrom, and allows machine learning models to predict the utility of drug candidates. The early-stage experiment result of the invention shows that the method not only can effectively discover new drugs by mining documents, but also can provide corresponding action mechanism for candidate drugs. It may be a complement to current traditional drug discovery methods. The knowledge-driven method is an effective drug reuse strategy and can support large-scale prediction and case research.
Is object orientation an inherent aspect of the shape of the object or is it represented separately and bound to the object shape in a similar way to other features, such as colour? This review brings together findings from neuropsychological studies of patients with agnosia for object orientation and experimental studies of object perception in healthy individuals that provide converging evidence of separate processing of object identity and orientation. Individuals with agnosia for object orientation, which typically results from damage to the right parietal lobe, can recognize objects presented in a range of orientations yet are unable to interpret or discriminate the objects' orientation. Healthy individuals tested with briefly presented objects demonstrate a similar dissociation: object identity is extracted rapidly in an orientation-invariant way, whereas processing the object's orientation is slower, requires attention and is influenced by the degree of departure from the canonical orientation. This asymmetry in processing can sometimes lead to incorrect bindings between the identity and orientation of objects presented in close temporal proximity. Overall, the available evidence indicates that object recognition is achieved in a largely orientation-invariant manner and that interpreting the object's orientation requires an additional step of mapping this orientation-invariant representation to a spatial reference frame.
Patients receive regorafenib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. If received as initial treatment, patients who experience disease progression may switch over to the other treatment regimen, per treating physician discretion.
The present invention discloses a non-woven fabric seasoning bag with high intensity and high-temperature resistance and a making method thereof. The non-woven fabric seasoning bag of the present invention is made of terylene filament non-woven fabric packing mixed seasoning. Terylene filament non-woven fabric packing materials are firstly loaded in a packing machine. The packing machine is then coated with silicon dioxide to laterally seal a warming mill and transversally seal the warming mill. The packing materials are in side seal, are then added to the mixed seasoning, are in transversal seal, and are packed to and fro and produced continuously. The seasoning bag of the present invention first adopts terylene filament non-woven fabric to be outer packing materials, and fundamentally solves the problem of the prior art that paper packing materials used by a tea bag has poor intensity and no high-temperature resistance.
The present invention discloses anti-hyperosteogeny medicine and a manufacturing method thereof. The anti-hyperosteogeny medicine has the prescriptions orderly according to weight shares: 90 to 220 shares of endothelium of Chinese red pine, 5 to 15 shares of raw oil of Chinese red pine, 10 to 35 shares of eucommia bark hide, 5 to 10 shares of dry ginger, 30 to 70 shares of realgar, 2 to 10 shares of white arsenic and 8 to 20 shares of lycoris radiata. The prescriptions are evenly mixed after respective processing. Each plaster is from 150 to 380g, and is packaged into a finished product by vacuum. A general patient only needs to apply one plaster to relieve pain and heal diseases. The present invention has the advantages of large medicine performance function, good healing effect, short treatment time, etc. Besides, the present invention can reduce patient's pain and save patient's expenses.
PURPOSE: A composition for treatment of male erectile dysfunction containing phentolamine and alprostadil in a buffer containing L-arginine and glycine is provided. It helps cause, promote and maintain an erection and increases or recovers human sexual reaction when injected into the corpora cavernosa of the penis. CONSTITUTION: The composition for treatment of male erectile dysfunction contains phentolamine and alprostadil in a buffer containing a substrate for nitric oxide synthesis. The phentolamine is phentolamine mesylate, phentolamine hydrochloride or phentolamine salts which meet pharmaceutical standards. The composition contains phentolamine mesylate and alprostadil in a weight ratio of abut 5:0.005 and in a concentration of about 0 to 10mg/ml and about 0 to 40mg/ml respectively. The substrate for nitric oxide synthesis is a mixture of L-arginine and glycine.
The invention discloses a medicine for preventing and treating chicken kidney swelling disease. The Chinese medicinal composition is prepared from the following Chinese medicinal herbs in a certain proportion: rhizoma Alismatis, Polyporus, Poria, herba Dianthi, folium Pyrrosiae, spora Lygodii, herba Leonuri, herba Artemisiae Scopariae, rhizoma corydalis, radix Clematidis, rhizoma Dioscoreae Septemlobae, herba Polygoni Avicularis, herba Lysimachiae, herba plantaginis, herba Taraxaci, caulis Akebiae, rhizoma Imperatae, radix Cyathulae, radix Et rhizoma Rhei, and Talcum. Pulverizing the above materials, grinding, mixing, and stirring. In clinical application, the medicine is soaked in boiling water for 30-60 minutes, so that the effective components of the medicine are fully dissolved and separated out, the absorption in the body of a sick chicken is facilitated, and a small amount of sugar and sodium bicarbonate are added to supplement energy, detoxify and regulate the acid-base balance of body fluid so as to improve the medicine effect. The medicine has high clinical cure rate, no adverse reaction, no medicine residue and no hidden danger of drug resistance. The medicine has the advantages of easily-accessible raw materials, simple preparation, definite therapeutic effect, and convenient use, and can be widely applied in chicken industry.
Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is one of the leading causes of admission to the intensive care unit, often triggered by a respiratory tract infection of bacterial or viral aetiology. Managing antibiotic therapy in this context remains a challenge. Respiratory panel molecular tests allow identifying viral aetiologies of AECOPD. We hypothesized that the systematic use of a respiratory multiplex PCR (mPCR) would help antibiotics saving in severe AECOPD. Our objectives were to describe the spectrum of infectious aetiologies of severe AECOPD, using a diagnostic approach combining conventional diagnostic tests and mPCR, and to measure antibiotics exposure. The study was bicentric, prospective, observational, and included 105 critically ill patients with a severe AECOPD of presumed infectious aetiology, in whom a respiratory mPCR with a viral panel was performed in addition to conventional microbiological tests. Altogether, the microbiological documentation rate was 50%, including bacteria alone (19%), respiratory viruses alone (16%), and mixed viruses and bacterial species (16%). The duration of antibiotic therapy was shorter in patients without documented bacterial infection (5.6 vs. 9 days; P = 0.0006). This pilot study suggests that molecular tests may help for the proper use of anti-infective treatments in critically ill patients with severe AECOPD.
Autoimmune uveitis (AU) is an inflammation of the uvea caused by either an autoimmune reaction to self-antigens or an innate inflammatory reaction secondary to an external stimulus. Corticosteroids are considered the gold standard in management of acute AU, but it is necessary to combine them with other immunosuppressive drugs. Finally, biological anti-inflammatory agents (for exapmle antagonists of tumor necrosis factor alpha like Infliximab and adalimumab) are also showing very promising results. Follow-up visits of subjects with uveitis must be frequent and focused on monitoring the recurrence of acute outbreaks, , if any. They should be aimed to determine the evolution of inflammatory signs until their complete resolution, thus ensuring the least possible consequences. After the initial phase of the treatment, the duration of use of the maintenance medication is directly related to the diagnosis, treatment and control of the underlying disease. This will help to determine if a patient is badly controlled and requires a more aggressive therapeutic plan. Also, a complete physical exam must be done each time the patient sees to the physician in order to monitor ophthalmological complications or development of adverse effects secondary to the treatment.
Medicaments for topical application for the treatment of psoriasis consist of an inert pharmaceutical carrier contg. an effective amount of prostaglandin E1 (PGE1) or prostaglandin E2, opt. together with a phosphodiesterase inhibitor (pref. theophylline, papaverin e or 5-chloro-6-ethylamino-1,3-dihydro-2H-imidazo 4,5-b pyrazin-2-one)- . Pref. medicaments contain 0.05-5 wt % PGE1 or PGE2 and 0.05-5 wt % phosphodiesterase inhibitor. The medicaments are pref. administered topically or by injection into the affected areas. Topical formulations include aerosol sprays, powder sprays, isotonic aqs. solns. lotions, creams, ointments, and solid salve sticks. The specification includes results of in vitro tests showing that PGE1 or PGE2 or their combinations with theophylline increase the concentration of cyclic AMP in normal human skin, psoriatic plaques, and 'normal adjoining' skin tissue. Present knowledge of the relationship between skin cyclic AMP concentrations and psoriasis indicates that PGE1 or PGE2, opt. together with a phosphodiesterase inhibitor, constitutes an effective treatment of psoriasis.
Robotic Exosuit Augmented Locomotion (REAL) refers to gait training with soft robotic exosuits, performed under a speed-based approach where participants are asked to walk at faster speeds in treadmill and overground environments. Cues and summary feedback emphasizing walking speed and forward propulsion are provided by the physical therapist to facilitate goal-directed walking practice. Training is progressively challenging based on environmental complexity and practice variability. REAL includes 12 training sessions, administered 2-3x/week. Each session includes 30 minutes of total walking time.
The embodiments herein disclose a method for synthesizing antagonistic peptide VEGF and bFGF. The method comprises synthesizing the antagonistic peptide for VEGF and bFGF and analyzing the purity of peptides. The quality of antagonistic peptide for VEGF and bFGF is analyzed by HPLC chromatogram and Mass spectrometry analysis. The biochemical activity of the antagonistic peptide for VEGF and bFGF is analyzed by competitive binding assay, cell proliferation assay, Matrigel assay for anti-angiogenic activity analysis, histopathological staining and Western blot analysis. The competitive binding assay of antagonistic peptide for VEGF and bFGF illustrate that peptides binds with cell receptors at a concentration of 2000 ng/ml. The cell proliferation assay illustrates that cell growth is arrested when antagonistic peptide for VEGF and bFGF are at a concentration of 2000 ng/ml. The anti-angiogenic activity analysis illustrates that angiogenesis is arrested when the concentration of antagonistic peptide for VEGF and bFGF is 2000 ng/ml.
PURPOSE: Activation by CD40 ligand (CD40L) of smooth muscle cells bearing CD40 on the surface of the cells is inhibited in vivo and ex vivo by contacting the cells with an agent capable of inhibiting interaction between CD40L and CD40 on the cells. In vivo inhibition of CD40-bearing smooth muscle cells is used to treat smooth muscle cell-dependent diseases. CONSTITUTION: Provided is a method of inhibiting activation by CD40 ligand of smooth muscle cells bearing CD40 on the cell surface, comprising contacting the cells with an agent capable of inhibiting interaction between CD40 ligand and CD40 on the cells, the agent being present in an amount effective to inhibit activation of the cells. In one embodiment of this invention the agent is capable of inhibiting any interaction between CD40 ligand and CD40. "Interaction between CD40 ligand and CD40 on the cells" refers to one or more aspects, functional or structural, of a CD40-CD40 ligand interrelationship. Therefore, in one embodiment, an agent which inhibits interaction may competitively bind to CD40 ligand in such a way to block or diminish the binding of CD40 ligand to cellular CD40. In another embodiment an agent which inhibits interaction may associate with CD40 or CD40 ligand in a manner which does not inhibit binding of CD40 ligand to cellular CD40, but which influences the cellular response to the CD40 ligation, such as by altering the turnover rate of the cellular CD40 or the CD40-agent complex, by altering binding kinetics of CD40 with CD40 ligand, or by altering the rate or extent of cellular activation in response to CD40 ligation.
WARNING: Administration of Carbon Dioxide may be hazardous or contraindicated. For use only by or under the supervision of a licensed practitioner who is experienced in the use and administration of Carbon Dioxide and is familiar with the indications, effects, dosages, methods and frequency and duration of administration, and the hazards, contraindications and side effects and the precautions to be taken. When used as a diluent for oxygen to produce respirable mixtures, user must assure sufficient oxygen concentration to sustain life.   
  
WARNING: CONTAINS GAS UNDER PRESSURE: MAY EXPLODE IF HEATED. MAY DISPLACE OXYGEN AND CAUSE RAPID SUFFOCATION. MAY CAUSE FROSTBITE. MAY INCREASE RESPIRATION AND HEART RATE. Do not handle until all safety precautions have been read an understood. Avoid breathing gas. Do not get in eyes, on skin, or on clothing. Use and store only outdoors or in a well-ventilated place. Use a back flow preventive device in the piping. Use only with equipment rated for cylinder pressure. Close valve after each use and whem empth. Protect from sunlight when ambient temperature exceeds 52°c (125°F). Read and follow the Safety Data Sheet (SDS) before use.   
  
FIRST AID: IF INHALED: Remove person to fresh air and keep comfortable for breathing. Get medical advice/attention. IF ON SKIN: Thaw frosted parts with lukewarm water. Do not rub affected area. Get immediate medical advice/attention.
Sensory processing begets movement. In persons with disorders of posture and movement due to cerebral palsy, an impaired ability to integrate multiple senses including pressure from ground, limb proprioception, and vestibular inputs leads to a movement pattern that is coarse, spastic and inefficient. In the pediatric rehab clinic spastic movement disorders have been treated with flexible, molded orthotics for the foot and ankle (AFO) to enhance sensation of ground reaction forces, and flexible elastomeric compression garments to enhance body and limb proprioception. While the investigators observed substantial improvements in gait quality and postural stability using sensory input orthotics, these clinical observations have not been objectively quantified. The goal is to use validated tools for measuring function and movement in pediatric populations in order to gather data on the value of sensory input orthotic interventions in children with cerebral palsy.

Under the term, sensory input orthotic, the following items are included which will be used in this study. 1) A flexible, thin polypropylene shell ankle-foot orthotic designed according to Hylton et al. Journal of P\&O 1989. 2) Wearable elastomeric compression garments manufactured by SPIO or from the Boston Brace DMO garment line. 3) A vibrating anklet that provides subsensory vibrational stimulation to the leg, manufactured by Accelera.
Peripheral venous catheter placement is one of the key tasks of an anesthesiologist, which needs to be completed before surgery in general anesthesia. The reported success rate of peripheral venous cannulation, when performed in a conventional manner, without any special technical tools which facilitate finding the peripheral vein, is only 51% during the first trial. However, up to 7% of patients require more than three cannulation trials. Ultrasound guidance of peripheral venous catheter insertion may increase success rate and shorten time to securing peripheral cannula. However, this approach has not been verified in the setting of operating theatre so far. This project aims to set the role of ultrasound guided venous cannulation in operating theatre.
This study is a school-based, randomised, controlled, parallel groups trial to examine the acute effect of breakfast (ready-to-eat-cereal and milk) vs. no breakfast on cognitive function and subjective state in 11-13 year old adolescents. It was hypothesised that the consumption of breakfast will have a positive acute effect on cognitive performance and subjective state compared with breakfast omission in 11-13 year olds. The study sample consisted of males and females aged 11-13 years who were recruited to take part in the study from a UK secondary school. There were two conditions in this parallel groups study: Breakfast and No breakfast (fasting). The breakfast intervention consisted of ad libitum intake of ready-to-eat-cereal with milk. Cognitive function was assessed at baseline and +70 and +215 minutes post-intervention. The Cambridge Neuro-psychological Test Automated Battery (CANTAB; Cambridge Cognition Ltd) was used to assess cognitive function. The battery included: Simple Reaction Time (SRT), 5-Choice Reaction Time (5-CRT), Rapid Visual Information Processing (RVIP), and Paired Associates Learning (PAL), which measured reaction time, visual-sustained attention, and visual-spatial memory respectively. Concomitant ratings of subjective mood, alertness, satiety, and motivation were taken throughout the morning using eight unipolar Visual Analogue Scales
In controlled clinical trials with CLOBEX® (clobetasol propionate) Lotion, 0.05%, the following adverse reactions have been reported: burning/stinging, skin dryness, irritation, erythema, folliculitis, pruritus, skin atrophy, and telangiectasia.

The pooled incidence of local adverse reactions in trials for psoriasis and atopic dermatitis with CLOBEX® (clobetasol propionate) Lotion, 0.05% at 1.0% or greater was:

Other local adverse events occurred at rates less than 1.0%. Similar rates of local adverse reactions were reported in the comparator (clobetasol propionate cream, 0.05%). Most local adverse events were rated as mild to moderate and they are not affected by age, race or gender.

The following additional local adverse reactions have been reported with topical corticosteroids. They may occur more frequently with the use of occlusive dressings and higher potency corticosteroids, including clobetasol propionate. These reactions are listed in an approximate decreasing order of occurrence: irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, striae and miliaria.